Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
暂无分享,去创建一个
M. Buti | R. Idilman | C. Yurdaydın | P. Lampertico | H. Janssen | R. Esteban | B. Hansen | V. Sypsa | G. Papatheodoridis | S. Savvidou | G. Dalekos | S. Manolakopoulos | M. Colombo | N. Gatselis | P. Arends | J. Goulis | G. Mangia | O. Keskin | C. Papaioannou | Kostantinos Galanis
[1] G. Papatheodoridis,et al. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. , 2013, World journal of gastroenterology.
[2] Yoshiyuki Suzuki,et al. Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.
[3] V. Wong,et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. , 2013, Gastroenterology.
[4] Kenta Yamamoto,et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. , 2013, Journal of hepatology.
[5] John F. Flaherty,et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.
[6] Y. Liaw,et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open‐label study , 2011, Hepatology.
[7] Vincent Wai-Sun Wong,et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. , 2011, The Lancet. Oncology.
[8] G. Touloumi,et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study , 2011, Gut.
[9] M. Buti,et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease , 2011, Hepatology.
[10] A. Lok,et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. , 2010, Journal of hepatology.
[11] V. Wong,et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Fattovich,et al. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. , 2008, Journal of hepatology.
[13] M. Yuen,et al. Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease , 2007, Antiviral therapy.
[14] George Kitis,et al. Outcome of hepatitis B e antigen–negative chronic hepatitis B on long‐term nucleos(t)ide analog therapy starting with lamivudine , 2005, Hepatology.
[15] Oliver N Keene,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.
[16] Pietro Andreone,et al. Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.
[17] G. Dusheiko,et al. Management of hepatocellular carcinoma. , 1992, Journal of hepatology.
[18] EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.
[19] M. Yuen,et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. , 2009, Journal of hepatology.